USA — Rival drugmakers Merck and Viatris have reached an agreement in their patent dispute over diabetes drugs Januvia and Janumet, pending approval from a judge. Attorneys for both companies…
Read MoreTag: Diabetes
FDA removes most doses of Ozempic from drug shortage list after Novo Nordisk resolves supply issues
USA — Novo Nordisk’s Ozempic, a treatment for type 2 diabetes and off-label for weight loss, is no longer on the FDA’s drug shortage list after months of limited supply.…
Read MoreABPI takes action against Novo Nordisk for violating code with Saxenda LinkedIn promotion
UNITED KINGDOM — Novo Nordisk has been suspended as a member of the Association of the British Pharmaceutical Industry (ABPI) for two years due to “serious breaches” of the trade…
Read MoreSanofi takes action: Lantus insulin to see major price drop in U.S. market
USA — Sanofi has announced that it will reduce the list price of Lantus, its most widely prescribed insulin in the U.S., by 78% and cap monthly costs at US$35…
Read MoreInsulin affordability in focus: Novo Nordisk and Eli Lilly lower prices in the US
USA — Novo Nordisk has followed in the footsteps of Eli Lilly by announcing a reduction in the prices of its insulin products in the United States two weeks after…
Read MoreEMA issues warning on Ozempic shortage and potential risks for diabetes patients
NETHERLANDS — The European Medicines Agency (EMA) has urged doctors to prioritize the diabetes drug Ozempic, manufactured by Novo Nordisk, for patients with diabetes who may be at risk if…
Read MoreSanofi to expand portfolio with US$2.9bn acquisition of Provention Bio
FRANCE — French drugmaker Sanofi has agreed to acquire US-based pharmaceutical firm Provention Bio for approximately US$2.9 billion to strengthen its general medicines portfolio with the US-approved type 1 diabetes…
Read MoreLawmakers seek to make insulin affordable with US$20 per vial price limit
USA — Senator Bernie Sanders, Chair of the Senate Health Committee, has introduced a new bill alongside a companion bill in the House that aims to set the price of…
Read MoreLilly takes steps to make insulin more affordable with price cuts and cost cap expansion
USA — Eli Lilly is set to reduce insulin prices and expand cost cap for insured patients, offering relief to those with diabetes who have to pay high annual costs…
Read MoreAstellas Pharma launches novel treatment for diabetic adults with CKD in Egypt
EGYPT – Astellas Pharma Inc. launched a novel treatment indicated for adult patients in Egypt with anemia associated with chronic kidney disease (CKD). According to the company statement, chronic kidney…
Read More